FORM AEC-374
(7-68)
10 CFR 30

U. S. ATOMIC ENERGY COMMISSION
BYPRODUCT MATERIAL LICENSE

Amendment No. 01

Pursuant to the Atomic Energy Act of 1954 and Title 10, Code of Federal Regulations, Chapter 1, Parts 30, 32, 33, 34, and 35, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, own, possess, transfer and import byproduct material listed below; and to use such byproduct material for the purpose(s) and at the place(s) designated below. This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, and is subject to all applicable rules, regulations, and orders of the Atomic Energy Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Woodland Medical Group	In accordance with application dated June 5, 1969,
2. 22341 W. Eight Mile Road Detroit, Michigan 48219	3. License number 21-13255-01 is amended in its entirety to read as follows:
	4. Expiration date May 31, 1974
	5. Reference No.

6. Byproduct material (element and mass number)	7. Chemical and/or physical form	8. Maximum amount of radioactivity which licensee may possess at any one time
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9. A. at locations specified in Condition 10
B. Iodine 131	B. Triiodothyronine	B. 1 millicurie
C. Iodine 131	C. Iodide	C. 30 millicuries
D. Phosphorus 32	D. Soluble phosphate	D. 10 millicuries

9. Authorized use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
B. In vitro studies.
C. Treatment of hyperthyroidism, cardiac dysfunction.
D. Treatment of leukemia, polycythemia vera, bone metastases.

CONDITIONS

10. Byproduct material may only be used at the licensee's address stated in Item 2 above.

11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 20, "Standards for Protection Against Radiation."

A12

License Number 21-13255-01

Amendment No. 01

(continued) CONDITIONS

12. Byproduct material shall be used by, or under the supervision of, Arthur A. Kaselemas, M.D.

13. Byproduct material to be administered to humans shall be procured in separated, prepackaged, precalibrated form from a supplier who manufactures or repackages the product under appropriate pharmaceutical controls related to assay, identity, quality, purity, sterility, and pyrogenicity.

14. Iodine 131 labeled Macroaggregated Iodinated Human Serum Albumin, Chromium 51 labeled Human Serum Albumin, and Iodine 131 labeled Colloidal (Microaggregated) Human Serum Albumin shall be procured from a supplier who holds an unsuspended or unrevoked license issued by the Secretary, Department of Health, Education, and Welfare, to propagate or manufacture and prepare, label, or distribute this material pursuant to Title 42, Chapter 1, Code of Federal Regulations, Part 73, "Biological Products."

Date AUG 0 6 1969

For the U. S. Atomic Energy Commission
Original Signed by
Cecil R. Buchanan
by Isotopes Branch 8-6-69
Division of Materials Licensing
Washington, D. C. 20545